This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Great Healthcare Stocks to Buy for 2019
by Swarup Gupta
Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.
Here's Why You Should Buy Express Scripts (ESRX) Stock Now
by Zacks Equity Research
Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.
Is Express Scripts Holding (ESRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ESRX) Outperforming Other Medical Stocks This Year?
Express Scripts Announces 3-Year Agreement With Walmart
by Zacks Equity Research
Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.
ESRX vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Should Value Investors Buy Express Scripts (ESRX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts (ESRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts (ESRX) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Express Scripts & Petco Tie Up, Ease Access to Pet Medicines
by Zacks Equity Research
Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
VanEck Launches 2 New ETFs: DURA and GOAT
by Zacks Equity Research
VanEck has rolled out two new ETFs DURA and GOAT which use stock selection and valuation methodologies developed by Morningstar Equity Research.
The Zacks Analyst Blog Highlights: Verizon, Express Scripts, Cigna, Ecolab and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Express Scripts, Cigna, Ecolab and eBay
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Reports for Verizon, Express Scripts & Cigna
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Express Scripts (ESRX), and Cigna (CI).
Stock Market News For Nov 1, 2018
by Zacks Equity Research
Wall Street ended a disastrous October on Wednesday on a winning note buoyed by strong third quarter earnings results from major brand names
Express Scripts (ESRX) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.
Express Scripts (ESRX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Express Scripts (ESRX) delivered earnings and revenue surprises of 0.41% and 2.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Q3 Earnings to Watch on Oct 31: ANTM, MOH, ESRX
by Zacks Equity Research
Healthcare stocks should gain from increase in revenues, higher premiums and enrollment partly offset by increase in expenses.
Express Scripts (ESRX) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Express Scripts (ESRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Express Scripts (ESRX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Express Scripts (ESRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Express Scripts (ESRX) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Express Scripts (ESRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Express Scripts' (ESRX) Q3 Earnings?
by Zacks Equity Research
Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.